<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rheumatoid arthritis and pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rheumatoid arthritis and pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Rheumatoid arthritis and pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bonnie L Bermas, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R O'Dell, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There is a female predominance among patients with rheumatoid arthritis (RA), and many of these patients are of childbearing age [<a href="#rid1">1</a>]. Thus, the management of RA during conception and pregnancy is a common challenge for rheumatologists and obstetricians. In many patients with RA, disease activity will improve in the gravid state. However, in patients whose RA flares or remains active during pregnancy, modification of treatment to minimize potential fetal toxicity while maintaining adequate disease control can be challenging.</p><p>The influence of RA upon fertility and pregnancy, the influence of pregnancy upon the disease, and the management of RA during conception, pregnancy, and lactation will be reviewed here. The use of antiinflammatory and immunosuppressive drugs in patients with rheumatic diseases during pregnancy and lactation, paternal use of antirheumatic drugs, and general principles in the management of RA are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a> and  <a class="medical medical_review" href="/z/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases"</a> and  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a>.)</p><p class="headingAnchor" id="H1533602192"><span class="h1">EFFECT OF RHEUMATOID ARTHRITIS ON FERTILITY</span><span class="headingEndMark"> — </span>Smaller family size has been observed in women with rheumatoid arthritis (RA) [<a href="#rid2">2-4</a>]. The reasons for this appear multifactorial and include patient choice, medication use during the usual period of family planning, and subfertility related to disease activity [<a href="#rid2">2-7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient preferences</strong> – According to two telephone surveys involving a total of approximately 1000 female patients, having RA negatively affected their decision to have children [<a href="#rid2">2,3</a>]; reasons cited included concerns over carrying the child, caring for the child, and passing RA on to biologic offspring, as well as concern that disease activity would be adversely impacted. Women diagnosed before age 18 and those who had not yet had children were more likely to have fewer pregnancies and children, compared with women diagnosed after age 30. Similarly, a Norwegian registry-based study also reported fewer pregnancies in women who were diagnosed with RA before having children [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced fertility in women with rheumatoid arthritis</strong> – In one survey of women with RA, over half of the respondents had fewer pregnancies than intended; of these women, 42 percent cited infertility as a reason [<a href="#rid3">3</a>]. Disease activity and medications have been cited as factors associated with reduced fertility in women with RA [<a href="#rid3">3,7-9</a>]. Additionally, one study [<a href="#rid8">8</a>], but not another [<a href="#rid5">5</a>], found evidence for reduced ovarian reserve in women with RA, based upon low age-adjusted serum anti-Müllerian hormone (AMH) levels. A more recent study demonstrated that increase in disease activity correlated with lower AMH levels; however, there was no significant difference in AMH levels between patients with RA and controls from the general population [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Longer time to conceive</strong> – Women with RA attempting to conceive have been found to have a longer time to pregnancy compared with women without RA [<a href="#rid9">9</a>]. A nationwide prospective cohort study in the Netherlands involving 245 women with RA attempting pregnancy or in their first trimester found that time to pregnancy exceeded 12 months in 42 percent of patients [<a href="#rid7">7</a>]; in addition to increased maternal age and nulliparity, RA-related factors associated with a longer time to pregnancy included increased disease activity and preconception use of nonsteroidal antiinflammatory drugs (NSAIDs) and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (greater than 7.5 mg/day). These findings suggest that maintaining good disease control prior to conception may decrease time to pregnancy. Factors that were not associated with a prolonged time to pregnancy included disease duration, smoking, being seropositive for rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA), use of <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ), and past use of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced fertility in men with rheumatoid arthritis</strong> – Few antirheumatic medications decrease sperm production. <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a>, a cytotoxic alkylating agent that is rarely used for rheumatoid vasculitis, can cause irreversible azoospermia that may induce permanent infertility. In addition, SSZ can cause reversible oligospermia but has a limited impact on fertility. The adverse effects of these medications on male fertility are described in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases", section on 'Adverse effects on spermatogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H2423974949"><span class="h1">EFFECTS OF PREGNANCY ON DISEASE ACTIVITY</span></p><p class="headingAnchor" id="H5"><span class="h2">Disease activity during pregnancy</span><span class="headingEndMark"> — </span>Approximately 50 to 70 percent of women with rheumatoid arthritis (RA) improve during pregnancy [<a href="#rid11">11-15</a>]. The decrease in disease activity generally starts in the first trimester and lasts through the duration of pregnancy. Though they may improve, half of women continue to have moderately to severely active RA through pregnancy [<a href="#rid16">16</a>].</p><p>Disease characteristics, such as duration of disease and functional class, do not appear to predict whether a patient will remit during pregnancy [<a href="#rid17">17,18</a>]. However, some data suggest that patients who lack both rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) are more likely to improve during pregnancy when compared with patients with either or both autoantibodies [<a href="#rid18">18</a>]. Other factors that may impact disease activity during pregnancy include the degree of human leukocyte antigen (HLA) class II disparity between mother and fetus. Several studies have shown that increased HLA class II disparity between mother and fetus is more likely to be associated with improvement in disease activity [<a href="#rid19">19,20</a>].</p><p>The immunologic effects of pregnancy, including the maternal-fetal immune interface and the systemic maternal immune response, are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3966.html" rel="external">"Immunology of the maternal-fetal interface"</a>.)</p><p>Not all studies have found improvement in symptoms with pregnancy. As an example, one report that evaluated the clinical course of 140 pregnant women with RA noted only minimal improvement in Health Assessment Questionnaire (HAQ) scores and in joint symptoms [<a href="#rid21">21</a>]. However, the results of the study should be interpreted with caution as the HAQ as an estimate of functionality is likely impacted by pregnancy itself [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Postpartum flare</span><span class="headingEndMark"> — </span>Disease flares of RA are common during the several months postpartum, occurring in nearly half of patients according to a 2019 meta-analysis [<a href="#rid15">15</a>]. In addition, one study suggested an increased risk of newly developing RA in the first three months postpartum, approaching 11-fold after a woman's first pregnancy [<a href="#rid13">13</a>].</p><p>RA pregnancies are associated with higher cesarean delivery rates. Whether this is driven by patient choice, provider choice, obstetrical factors, or medical indication is unclear [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H2695412328"><span class="h1">PREGNANCY OUTCOME</span><span class="headingEndMark"> — </span>Pregnancy outcomes in women with well-controlled rheumatoid arthritis (RA) are comparable to those in the general population. However, patients with active disease may be at higher risk of adverse obstetric outcomes; overall, these risks are increased 1.4- to 2.2-fold compared with controls, including hypertensive disorders (11.1 versus 7.8 percent), intrauterine growth restriction (3.4 versus 1.6 percent), and cesarean delivery (37.2 versus 26.5 percent) [<a href="#rid23">23</a>]. Similarly, in a Danish study of 1739 RA pregnancies, women with higher levels of disease activity had a greater risk of preterm birth and small for gestational age infants [<a href="#rid24">24</a>].</p><p>Most reports have failed to show any increase in fetal morbidity or fetal losses in women with RA [<a href="#rid25">25,26</a>]. In a nationwide cohort study in Denmark of 1,917,723 children born between 1977 and 2008, including 13,556 children exposed to maternal RA or maternal preclinical RA [<a href="#rid27">27</a>], children born to mothers with RA were more likely to be born preterm (odds ratio [OR] 1.48, 95% CI 1.20-1.84), as were children of mothers in whom the diagnosis of RA was made following but not before the birth (OR 1.32, 95% CI 1.07-1.64). Even after adjusting for maternal age at birth, parity (one, two, or three), maternal education, smoking status, and mother's country of origin (Denmark or outside Denmark), the effects of several factors associated with preterm birth were not analyzed, including medication use and disease activity during pregnancy. The birth weight of children of mothers with RA or preclinical RA was also slightly reduced (87 grams) compared with children of mothers without RA. Paternal RA did not affect rates of either preterm birth or birth weight.</p><p class="headingAnchor" id="H14"><span class="h1">MANAGEMENT APPROACH</span><span class="headingEndMark"> — </span>For women with rheumatoid arthritis (RA), counseling prior to conception, coordinated care among specialists, and medication management with shared decision-making are all important. Therapeutic choices are governed not only by disease severity but also by concerns regarding fetal teratogenicity and toxicity. Thus, the benefits and risks of antirheumatic therapeutics for the individual patient and her fetus are important considerations [<a href="#rid28">28-31</a>].</p><p>The approach to management is described here, and a more detailed discussion of the evidence regarding the safety and use of specific antiinflammatory and immunosuppressive medications in pregnancy and during lactation are presented in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p>Our approach to the treatment of patients with RA prior to and during pregnancy is generally consistent with the recommendations of the American College of Rheumatology (ACR) [<a href="#rid32">32</a>] and other major professional organizations  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>) [<a href="#rid33">33,34</a>]:</p><p class="headingAnchor" id="H15"><span class="h2">Prior to pregnancy</span></p><p class="headingAnchor" id="H1760258063"><span class="h3">Preconception counseling and testing</span></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with RA who are contemplating pregnancy, it is helpful for the rheumatologist, obstetrician, and patient to discuss potential fertility issues, pregnancy outcomes in RA, disease activity during pregnancy and in the postpartum period, and medication use in the preconception period and during pregnancy and lactation. The benefits of keeping disease under good control must be balanced with the risk of any medications that are used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with active RA should be managed by both a rheumatologist and a maternal fetal medicine specialist during pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should plan pregnancy when their disease is under good control on medications compatible with pregnancy (eg, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> [SSZ], <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [HCQ], a tumor necrosis factor [TNF] alpha inhibitor)  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). Patients who are receiving medications for RA with a moderate to high risk of fetal harm (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [MTX] and <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> [LEF]) should use highly effective contraceptive methods such as long-acting reversible contraceptives (LARCs). (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection", section on 'Discuss method characteristics'</a> and  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types"</a> and  <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As recommended by the ACR, patients with RA should be tested for anti-Ro/SSA and anti-La/SSB antibodies once before or early in pregnancy, due to their associated increase in risk for neonatal lupus [<a href="#rid32">32</a>]. Given the relative persistence of these antibodies when present, repeat testing during pregnancy is not required. Screening and testing for these antibodies and for fetal heart block and other features of neonatal lupus are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">"Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Screening and surveillance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with extensive cervical spine involvement due to RA should have an anesthesiology evaluation in case urgent surgery requiring intubation occurs. (See  <a class="medical medical_review" href="/z/d/html/7518.html" rel="external">"Cervical subluxation in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/1826.html" rel="external">"Preoperative evaluation and perioperative management of patients with rheumatic diseases", section on 'Rheumatoid arthritis'</a>.)</p><p></p><p class="headingAnchor" id="H3912178270"><span class="h3">Medication management before pregnancy</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a><strong> supplementation</strong> – Patients should start folic acid supplementation prior to pregnancy once conception is being attempted; the appropriate dose is included in a prenatal multivitamin. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAIDs</strong> – In women who have had recurrent (ie, two or more) first trimester losses and in those experiencing difficulty in conceiving, one can consider discontinuing nonsteroidal antiinflammatory drugs (NSAIDs)  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). There are case reports and some small series that have shown transient infertility, which appears to be mediated by inhibition of the rupture of the luteinized follicle, in some women treated with NSAIDs. Data in animals have also suggested that NSAIDs may interfere with ovulation and implantation. There are conflicting data regarding an increased risk of spontaneous abortion after NSAID use during the first trimester. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'NSAIDs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – The fluorinated glucocorticoids, such as <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, cross the placenta at higher concentrations without significant metabolism to inactive metabolites, and they can be used to hasten lung maturity in cases of expectant delivery of premature infants, but would not be used routinely for the management of active RA, particularly during pregnancy  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). Glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, and <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>) should be maintained at the lowest dose possible. Nonfluorinated glucocorticoids, including prednisone, prednisolone, and methylprednisolone, cross the placenta at very low concentrations and are largely metabolized to inactive metabolites in the placenta before reaching the fetus; thus, they are relatively safe to use during pregnancy in low to moderate doses. Dosing should kept as low as possible as doses of oral glucocorticoids of &gt;10 mg prednisone equivalent has been associated with increased risk of preterm birth [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/4679.html" rel="external">"Pregnancy in women with systemic lupus erythematosus", section on 'Selective use allowed during pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> – HCQ crosses the placenta  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). However, most studies have not described fetal toxicity with HCQ doses used for the treatment of systemic lupus erythematosus (SLE) or other rheumatic diseases [<a href="#rid36">36-38</a>]. One population-based cohort study of rheumatic disease patients involving 2045 HCQ-exposed pregnancies and 21,679 matched pregnancies not exposed to HCQ showed that HCQ use during the first trimester was associated with a small increased risk of major congenital malformations (adjusted relative risk 1.26, 95% CI 1.04-1.54) [<a href="#rid39">39</a>]. The absolute risk for exposed infants was slightly higher than in unexposed infants of autoimmune rheumatic disease patients (5.48 versus 4.32 percent). However, no particular pattern of malformations was identified. Moreover, this study did not account for variables not included in the data set, such as use of alcohol, tobacco, <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>, other drugs, and over-the-counter medications, as well as unidentified confounders [<a href="#rid40">40</a>]. The benefits of HCQ during pregnancy discussed below outweigh the potential risks raised by the aforementioned study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> – MTX should be stopped at least one to three months prior to conception in women because of its teratogenic risk and should be avoided throughout pregnancy  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). If conception occurs in a woman taking MTX, the medication should be stopped immediately and <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> 5 mg/day taken for the duration of the pregnancy. Referral to a high-risk obstetrician can be useful to ascertain the risk for congenital anomalies and determine optimal pregnancy management in this situation. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Methotrexate'</a>.)</p><p></p><p class="bulletIndent1">The use of MTX in men prior to or around the time of conception does not appear to have adverse consequences for fertility or pregnancy outcomes and is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> – Pregnancy should be avoided in patients on LEF until undetectable serum concentrations (&lt;0.02 mg/L) are verified because of reports of teratogenicity in animals  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Leflunomide'</a>). This can be achieved by discontinuation of this medication two years prior to conception or by the use of an enhanced drug elimination procedure using <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a>. (See  <a class="medical medical_review" href="/z/d/html/7515.html" rel="external">"Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1">Despite these concerns, there have been several reassuring studies that have not shown an increased risk of congenital anomalies or spontaneous abortions in pregnancies with LEF exposure. One report of data from a Canadian registry did not find an increased incidence of congenital anomalies or spontaneous abortions in their cohort of 72 pregnancies and births exposed to LEF [<a href="#rid41">41</a>]. Several other studies also reported no increased risk of congenital anomalies in LEF-exposed pregnancies [<a href="#rid42">42-44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TNF inhibitors, other biologics, and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs)</strong> – In patients with active disease who are on tumor necrosis factor (TNF) alpha inhibitors, these medications can be continued  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). Most professional societies recommend discontinuing these medications in the third trimester, although in patients with active disease, one may continue these medications through delivery if critically important for disease control. Certolizumab is pegylated and does not cross the placenta in significant amounts and can be continued throughout pregnancy. (See <a class="local">'During pregnancy'</a> below.)</p><p></p><p class="bulletIndent1">There are insufficient data to draw conclusions regarding the safety of the other biologics or tsDMARDs (ie, Janus kinase [JAK] inhibitors) during pregnancy; thus, these medications should be discontinued prior to pregnancy.</p><p></p><p class="headingAnchor" id="H16"><span class="h2">During pregnancy</span></p><p class="headingAnchor" id="H3162189841"><span class="h3">General and obstetric care</span><span class="headingEndMark"> — </span>Several issues may modify routine obstetric practice and care in women with RA:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with RA can be seen at typical intervals for pregnancy management except in the case of active RA or for a specific obstetric concern that requires more frequent care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pregnancy complications such as gestational diabetes, pregnancy-induced hypertension, and preeclampsia should be followed accordingly based upon usual obstetric practice. (See  <a class="medical medical_review" href="/z/d/html/4800.html" rel="external">"Gestational diabetes mellitus: Obstetric issues and management"</a> and  <a class="medical medical_review" href="/z/d/html/6805.html" rel="external">"Gestational hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with anti-Ro/SSA and anti-La/SSB antibodies should be screened and managed accordingly. (See <a class="local">'Preconception counseling and testing'</a> above and  <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">"Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Screening and surveillance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with RA should not be delivered early unless indicated for obstetric reasons.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Usual management is performed for patients who require a cesarean delivery, other than particular attention to the risks of intubation in patients with cervical spine disease. (See <a class="local">'Preconception counseling and testing'</a> above and  <a class="medical medical_review" href="/z/d/html/7518.html" rel="external">"Cervical subluxation in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/1826.html" rel="external">"Preoperative evaluation and perioperative management of patients with rheumatic diseases", section on 'Rheumatoid arthritis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recommendations for exercise and physical activity do not differ for most patients with RA from other pregnant women, except when modifications may be required because of limitations due to active arthritis or prior joint injury or deformity. (See  <a class="medical medical_review" href="/z/d/html/412.html" rel="external">"Exercise during pregnancy and the postpartum period"</a> and  <a class="medical medical_review" href="/z/d/html/7498.html" rel="external">"Nonpharmacologic therapies for patients with rheumatoid arthritis", section on 'Physical activity and exercise'</a>.)</p><p></p><p class="headingAnchor" id="H77337042"><span class="h3">Medication management during pregnancy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAIDs, including </strong><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> – In patients whose RA becomes active during pregnancy, nonsteroidal antiinflammatory drugs (NSAIDs) can be used and are generally considered safe until week 20; however, from 20 weeks on, NSAIDs should be avoided, with the exception of low-dose aspirin being given for obstetric-related indications, because of the rare risk of fetal renal compromise and oligohydramnios  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). After week 30, there is an increased risk of premature closure of the ductus arteriosus and inhibition of labor. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Aspirin (low dose)'</a>.)</p><p></p><p class="bulletIndent1">There are insufficient data on the safety of selective cyclooxygenase 2 (COX-2) inhibitors during pregnancy; therefore, these drugs should be avoided.</p><p></p><p class="bulletIndent1">There are only limited data regarding moderate- to high-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, which should be avoided throughout pregnancy. This is in distinction to low-dose aspirin (81 mg/day), which is sometimes used as part of the management of antiphospholipid syndrome and for prevention of preeclampsia. Adverse effects reported in the fetus following maternal use of high-dose aspirin include mortality, intrauterine growth retardation, salicylate intoxication, bleeding abnormalities, and neonatal acidosis [<a href="#rid45">45-47</a>]. Use of high-dose aspirin close to delivery may cause premature closure of the ductus arteriosus. Adverse effects reported in the mother include anemia, hemorrhage, prolonged gestation, and prolonged labor.</p><p></p><p class="bulletIndent1">Evidence regarding the safety of NSAIDs and low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> use during pregnancy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'NSAIDs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – In patients in whom NSAIDs are inadvisable or inadequate, we use the lowest dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> necessary for disease control  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). We try to limit prednisone dosing to no more than 10 mg/day. Our approach to the use of stress-dose glucocorticoids for women undergoing a cesarean delivery is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/146.html" rel="external">"The management of the surgical patient taking glucocorticoids"</a> and <a class="local">'Medication management before pregnancy'</a> above and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)</strong> – HCQ, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ), and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (AZA) can be continued and used in patients with an inadequate response to NSAIDs or <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). For moderately active disease, patients can be maintained on HCQ and/or SSZ. Evidence regarding the safety of these medications is described separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Hydroxychloroquine'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Sulfasalazine'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Azathioprine and 6-mercaptopurine'</a>.)</p><p></p><p class="bulletIndent1">Neither MTX nor LEF should be used during pregnancy, as discussed in detail separately. (See <a class="local">'Medication management before pregnancy'</a> above and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Methotrexate'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Leflunomide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TNF inhibitors</strong> – Tumor necrosis factor (TNF) inhibitors may be continued during pregnancy  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). However, the duration of use depends upon the specific agent and the balance of individual risks and benefits. Our approach to the use of TNF inhibitors is generally consistent with the guidelines of the ACR, the European Alliance of Associations for Rheumatology (formerly the European League Against Rheumatism; EULAR), and the British Society for Rheumatology (BSR)/British Health Professionals in Rheumatology (BHPR) [<a href="#rid32">32-34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> should be discontinued in the third trimester [<a href="#rid33">33</a>], although the use of these drugs can be extended, if necessary, to a later gestational age if benefits of disease control outweigh potential risks for an individual patient [<a href="#rid34">34</a>]. The major concern has been that continuing TNF alpha blockade may increase the risk of neonatal infection; however, available data have not shown a statistically significant increased risk of infection in neonates after exposure in utero to TNF alpha blockade [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tumor necrosis factor inhibitors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Certolizumab may be continued throughout pregnancy. It crosses the placenta in low to undetectable amounts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs)</strong> – Biologics that contain an immunoglobulin, such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, do not cross the placenta in significant amounts until week 12 of gestation. Thus, these medications can be continued up until conception. There are insufficient data to conclude pregnancy safety for the small molecule tsDMARDs such as the JAK inhibitors  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>).</p><p></p><p class="headingAnchor" id="H17"><span class="h3">Resistant or flaring disease activity</span></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids (oral or intraarticular) can be used to manage disease flares or persistent moderately to highly active disease that is not adequately controlled with other medications. Glucocorticoid therapy during pregnancy may increase the risk of premature rupture of the membranes (PROM) and intrauterine growth restriction [<a href="#rid50">50,51</a>]. In addition, oral glucocorticoids can increase the risk of preterm birth [<a href="#rid35">35</a>]. In the mother, oral glucocorticoids may increase the risk of pregnancy-induced hypertension, gestational diabetes, osteoporosis, and infection [<a href="#rid47">47</a>]. The lowest effective dose of glucocorticoids should be used. (See <a class="local">'Medication management before pregnancy'</a> above and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with disease refractory to routine management or with continued flares during pregnancy despite the use of glucocorticoids, if not already taking these medications, TNF inhibitors can be used  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). (See <a class="local">'Medication management during pregnancy'</a> above and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tumor necrosis factor inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H3835319901"><span class="h1">POSTPARTUM MANAGEMENT</span></p><p class="headingAnchor" id="H3474082696"><span class="h2">Postpartum management of rheumatoid arthritis</span><span class="headingEndMark"> — </span>For patients who are clinically quiescent in the postpartum period, the pregnancy medication regimen can be continued. For women who flare postpartum or who have a high likelihood of flaring, their prepregnancy regimen can be resumed with adjustment to medications for women who are breastfeeding. (See <a class="local">'Medication use during breastfeeding'</a> below.)</p><p>The demands of caring for a newborn can be particularly challenging in women with rheumatoid arthritis (RA) who are flaring in the postpartum period or who have restricted joint mobility. Patients with RA may need additional support or help during this time.</p><p class="headingAnchor" id="H18"><span class="h2">Medication use during breastfeeding</span><span class="headingEndMark"> — </span>The majority of antirheumatic medications are compatible with breastfeeding, although there are certain antirheumatic medications that should be avoided during breastfeeding. Many of these restrictions pertain to the same medications for which use is restricted during pregnancy  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>) [<a href="#rid32">32</a>]. The evidence regarding the safety of maternal use of antirheumatic disease medications during lactation is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal antiinflammatory drugs (NSAIDs) can be used, but <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be avoided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> can be taken in low doses. In patients taking 20 mg/day or greater, waiting at least four hours after the dose prior to nursing is sufficient to substantially reduce exposure to the nursing child.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> (HCQ) is compatible with nursing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> (SSZ) is generally compatible with breastfeeding in healthy, full-term infants. SSZ is transferred in low concentration into breast milk and is considered compatible with breastfeeding However, women taking SSZ should avoid breastfeeding premature infants or those with hyperbilirubinemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency. A case of bloody diarrhea has been reported in a newborn exposed to this medication during nursing, and diarrhea during breastfeeding may require discontinuation of nursing. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Sulfasalazine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biologics such as tumor necrosis factor (TNF) alpha inhibitors, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">sarilumab</a>, and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> can be continued or initiated during lactation. These biologic agents are large molecules and therefore reach the breast milk in low concentration. Furthermore, they are unlikely to be effectively absorbed orally by the newborn.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> (AZA) is considered compatible with breastfeeding. Excretion in breast milk is very low in most patients. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Azathioprine and 6-mercaptopurine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (MTX), <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> (LEF), <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> should be avoided in nursing women.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Janus kinase (JAK) inhibitors and other targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) should be avoided in lactating women as these agents readily transfer into breast milk.</p><p></p><p>In patients who flare during the postpartum period, attention should be given to the use of medications compatible with nursing. In those patients who choose not to breastfeed, their prepregnancy medications can be resumed.</p><p class="headingAnchor" id="H3357593859"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16275.html" rel="external">"Patient education: Rheumatoid arthritis and pregnancy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/510.html" rel="external">"Patient education: Rheumatoid arthritis and pregnancy (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/583.html" rel="external">"Patient education: Disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H95776428"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy and disease activity</strong> – Approximately 50 to 70 percent of women with rheumatoid arthritis (RA) experience a reduction in disease activity during pregnancy. This reduction generally starts in the first trimester and lasts for several weeks or months into the postpartum period. However, roughly one-half of patients eventually flare during the postpartum period, usually within the first three months. There may also be an increased risk of developing RA in the first three months postpartum, particularly after a woman’s first pregnancy. (See <a class="local">'Disease activity during pregnancy'</a> above and <a class="local">'Postpartum flare'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy outcomes</strong> – RA does not increase fetal losses. There is a higher rate of intrauterine growth restriction, pregnancy-induced hypertension, and cesarean delivery among RA patients compared with the general population. (See <a class="local">'Pregnancy outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic medication management in the preconception, prenatal, and breastfeeding period</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients using glucocorticoids</strong> – Most patients can continue or use glucocorticoids during pregnancy and breastfeeding, using the lowest dose necessary for disease control  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). Nonfluorinated glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>) do not cross the placenta and are safe to use at low to moderate doses. However, prednisone doses greater than 10 mg/day (or equivalent glucocorticoid) may be associated with preterm birth.</p><p></p><p class="bulletIndent2">Fluorinated glucocorticoids (eg, <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>) cross the placenta and are not typically used in pregnant patients with RA. (See <a class="local">'Medication management during pregnancy'</a> above and <a class="local">'Medication use during breastfeeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients using nonsteroidal antiinflammatory drugs</strong> – Women who have had two or more first trimester losses or have difficulty conceiving should stop taking nonsteroidal antiinflammatory drugs (NSAIDs), which have been associated with transient infertility. NSAIDs can be used safety through week 20 of gestation but should not be used during the second half of pregnancy because of the risk for oligohydramnios  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). Moderate- to high-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be avoided throughout pregnancy. NSAIDs other than aspirin can be used safely during breastfeeding. (See <a class="local">'Medication management before pregnancy'</a> above and <a class="local">'Resistant or flaring disease activity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients using conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> – Methotrexate (MTX) should be stopped one to three months prior to conception and should not be restarted until the patient is no longer breastfeeding  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> – Pregnancy should be avoided in patients on leflunomide (LEF) until undetectable serum concentrations are verified  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). LEF should not be restarted until the patient is no longer breastfeeding.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a><strong> and </strong><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> – Both hydroxychloroquine (HCQ) and azathioprine (AZA) are safe for use during pregnancy and breastfeeding  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> – Sulfasalazine (SSZ) may be used throughout pregnancy  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). SSZ may also be used during breastfeeding except when the infant has hyperbilirubinemia, has glucose-6-phosphate dehydrogenase deficiency, or is premature. (See <a class="local">'Medication management before pregnancy'</a> above and <a class="local">'Medication management during pregnancy'</a> above and <a class="local">'Medication use during breastfeeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients using biologic (b) DMARDs</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Tumor necrosis factor inhibitors</strong> – These can be continued through the first two trimesters of pregnancy  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> should generally be discontinued in the third trimester because of a theoretical risk of neonatal infection, although they can be used in late pregnancy on a case-by-case basis. Certolizumab may be continued during the entire pregnancy, since PEGylation prevents it from crossing the placenta. All tumor necrosis factor (TNF) inhibitors are compatible with breastfeeding.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Other bDMARDs</strong> – Biologics that contain an immunoglobulin, such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, do not cross the placenta in significant amounts until week 12 of gestation. Thus, these medications may be used throughout pregnancy and breastfeeding  (<a class="graphic graphic_table graphicRef141979" href="/z/d/graphic/141979.html" rel="external">table 1</a>). (See <a class="local">'Medication management during pregnancy'</a> above and <a class="local">'Medication use during breastfeeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients using targeted synthetic (ts) DMARDs</strong> – Janus kinase (JAK) inhibitors should be discontinued prior to pregnancy and should not be restarted until the patient is no longer breastfeeding. (See <a class="local">'Medication management before pregnancy'</a> above and <a class="local">'Medication use during breastfeeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flare management during pregnancy</strong> – In patients whose RA becomes active during pregnancy, we advise limited use of NSAIDs, which can be given up to week 20. If NSAIDs are inadequate, we try to use no more than 10 mg/day <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to achieve disease control. HCQ and SSZ can be used in patients with an inadequate response to NSAIDs or prednisone. TNF inhibitors can be initiated if patients flare. (See <a class="local">'During pregnancy'</a> above and <a class="local">'Resistant or flaring disease activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flare management while breastfeeding</strong> – Women who are breastfeeding can use NSAIDs, but <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be avoided. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> can be taken in low doses; when the dose is 20 mg/day or more, patients should wait at least four hours prior to nursing. In patients whose symptoms recur during the postpartum period, TNF inhibitors, HCQ, and AZA may be used. SSZ is also compatible with nursing except when the infant has hyperbilirubinemia, has glucose-6-phosphate dehydrogenase deficiency, or is premature. Breastfeeding patients should avoid MTX, LEF, JAK inhibitors, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>. (See <a class="local">'Medication use during breastfeeding'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dugowson CE, Koepsell TD, Voigt LF, et al. Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987-1989. Arthritis Rheum 1991; 34:1502.</a></li><li><a class="nounderline abstract_t">Katz PP. Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum 2006; 55:217.</a></li><li><a class="nounderline abstract_t">Clowse ME, Chakravarty E, Costenbader KH, et al. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64:668.</a></li><li><a class="nounderline abstract_t">Wallenius M, Skomsvoll JF, Irgens LM, et al. Parity in patients with chronic inflammatory arthritides childless at time of diagnosis. Scand J Rheumatol 2012; 41:202.</a></li><li><a class="nounderline abstract_t">Brouwer J, Laven JS, Hazes JM, et al. Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65:1534.</a></li><li><a class="nounderline abstract_t">KAY A, BACH F. SUBFERTILITY BEFORE AND AFTER THE DEVELOPMENT OF RHEUMATOID ARTHRITIS IN WOMEN. Ann Rheum Dis 1965; 24:169.</a></li><li><a class="nounderline abstract_t">Brouwer J, Hazes JM, Laven JS, Dolhain RJ. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 2015; 74:1836.</a></li><li><a class="nounderline abstract_t">Henes M, Froeschlin J, Taran FA, et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels. Rheumatology (Oxford) 2015; 54:1709.</a></li><li><a class="nounderline abstract_t">Jawaheer D, Zhu JL, Nohr EA, Olsen J. Time to pregnancy among women with rheumatoid arthritis. Arthritis Rheum 2011; 63:1517.</a></li><li><a class="nounderline abstract_t">Valdeyron C, Soubrier M, Pereira B, et al. Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohort. Rheumatology (Oxford) 2021; 60:1863.</a></li><li><a class="nounderline abstract_t">Hench PS. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrosis and intermittent hydrarthrosis. Mayo Clin Proc 1938; 13:161.</a></li><li><a class="nounderline abstract_t">Persellin RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1976-1977; 27:922.</a></li><li><a class="nounderline abstract_t">Silman A, Kay A, Brennan P. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 1992; 35:152.</a></li><li><a class="nounderline abstract_t">Ostensen M. The influence of pregnancy on blood parameters in patients with rheumatic disease. Scand J Rheumatol 1984; 13:203.</a></li><li><a class="nounderline abstract_t">Jethwa H, Lam S, Smith C, Giles I. Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis. J Rheumatol 2019; 46:245.</a></li><li><a class="nounderline abstract_t">de Man YA, Dolhain RJ, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008; 59:1241.</a></li><li><a class="nounderline abstract_t">Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997; 23:195.</a></li><li><a class="nounderline abstract_t">de Man YA, Bakker-Jonges LE, Goorbergh CM, et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Ann Rheum Dis 2010; 69:420.</a></li><li><a class="nounderline abstract_t">Zrour SH, Boumiza R, Sakly N, et al. The impact of pregnancy on rheumatoid arthritis outcome: the role of maternofetal HLA class II disparity. Joint Bone Spine 2010; 77:36.</a></li><li><a class="nounderline abstract_t">Nelson JL, Hughes KA, Smith AG, et al. Remission of rheumatoid arthritis during pregnancy and maternal-fetal class II alloantigen disparity. Am J Reprod Immunol 1992; 28:226.</a></li><li><a class="nounderline abstract_t">Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 1999; 42:1219.</a></li><li><a class="nounderline abstract_t">de Man YA, Hazes JM, van de Geijn FE, et al. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57:716.</a></li><li><a class="nounderline abstract_t">Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:899.</a></li><li><a class="nounderline abstract_t">Hellgren K, Secher AE, Glintborg B, et al. Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark. Rheumatology (Oxford) 2022; 61:3711.</a></li><li><a class="nounderline abstract_t">Morris WI. Pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Aust N Z J Obstet Gynaecol 1969; 9:136.</a></li><li><a class="nounderline abstract_t">Ostensen M, Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 1983; 26:1155.</a></li><li><a class="nounderline abstract_t">Rom AL, Wu CS, Olsen J, et al. Fetal growth and preterm birth in children exposed to maternal or paternal rheumatoid arthritis: a nationwide cohort study. Arthritis Rheumatol 2014; 66:3265.</a></li><li><a class="nounderline abstract_t">Soscia PN, Zurier RB. Drug therapy of rheumatic diseases during pregnancy. Bull Rheum Dis 1992; 41:1.</a></li><li><a class="nounderline abstract_t">Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.</a></li><li><a class="nounderline abstract_t">Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995; 38:1722.</a></li><li><a class="nounderline abstract_t">Roubenoff R, Hoyt J, Petri M, et al. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988; 18:88.</a></li><li><a class="nounderline abstract_t">Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020; 72:529.</a></li><li><a class="nounderline abstract_t">Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016; 55:1693.</a></li><li><a class="nounderline abstract_t">Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75:795.</a></li><li><a class="nounderline abstract_t">Palmsten K, Bandoli G, Vazquez-Benitez G, et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology (Oxford) 2020; 59:1262.</a></li><li><a class="nounderline abstract_t">Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996; 23:1715.</a></li><li><a class="nounderline abstract_t">Buchanan NM, Toubi E, Khamashta MA, et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996; 55:486.</a></li><li><a class="nounderline abstract_t">Cooper WO, Cheetham TC, Li DK, et al. Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. Arthritis Rheumatol 2014; 66:444.</a></li><li><a class="nounderline abstract_t">Huybrechts KF, Bateman BT, Zhu Y, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol 2021; 224:290.e1.</a></li><li><a class="nounderline abstract_t">Bermas BL, Chambers C. Hydroxychloroquine early in pregnancy and risk of birth defects: don't throw out the baby with the bathwater. Am J Obstet Gynecol 2021; 224:548.</a></li><li><a class="nounderline abstract_t">Bérard A, Zhao JP, Shui I, Colilla S. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis 2018; 77:500.</a></li><li><a class="nounderline abstract_t">Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010; 62:1494.</a></li><li><a class="nounderline abstract_t">Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012; 64:2085.</a></li><li><a class="nounderline abstract_t">Henson LJ, Afsar S, Davenport L, et al. Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. Reprod Toxicol 2020; 95:45.</a></li><li><a class="nounderline abstract_t">Corby DG. Aspirin in pregnancy: maternal and fetal effects. Pediatrics 1978; 62:930.</a></li><li><a class="nounderline abstract_t">Ostensen M. Nonsteroidal anti-inflammatory drugs during pregnancy. Scand J Rheumatol Suppl 1998; 107:128.</a></li><li><a class="nounderline abstract_t">Østensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8:209.</a></li><li><a class="nounderline abstract_t">Chaparro M, Verreth A, Lobaton T, et al. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. Am J Gastroenterol 2018; 113:396.</a></li><li><a class="nounderline abstract_t">Vinet É, De Moura C, Pineau CA, et al. Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. Arthritis Rheumatol 2018; 70:1565.</a></li><li><a class="nounderline abstract_t">Guller S, Kong L, Wozniak R, Lockwood CJ. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. J Clin Endocrinol Metab 1995; 80:2244.</a></li><li><a class="nounderline abstract_t">Lockwood CJ, Radunovic N, Nastic D, et al. Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy. J Perinat Med 1996; 24:243.</a></li></ol></div><div id="topicVersionRevision">Topic 7514 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1747134" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987-1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16583405" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Childbearing decisions and family size among women with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22344961" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22360422" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Parity in patients with chronic inflammatory arthritides childless at time of diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23554429" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14293676" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : SUBFERTILITY BEFORE AND AFTER THE DEVELOPMENT OF RHEUMATOID ARTHRITIS IN WOMEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24833784" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fertility in women with rheumatoid arthritis: influence of disease activity and medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25957439" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21380995" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Time to pregnancy among women with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33147613" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrosis and intermittent hydrarthrosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/799947" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of pregnancy on rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734904" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Timing of pregnancy in relation to the onset of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6333068" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The influence of pregnancy on blood parameters in patients with rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30385703" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759316" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9031383" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pregnancy and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19282308" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031464" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The impact of pregnancy on rheumatoid arthritis outcome: the role of maternofetal HLA class II disparity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1285885" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Remission of rheumatoid arthritis during pregnancy and maternal-fetal class II alloantigen disparity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10366115" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530669" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508972" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34864891" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5260310" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pregnancy in rheumatoid arthritis and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6615567" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25393524" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fetal growth and preterm birth in children exposed to maternal or paternal rheumatoid arthritis: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600444" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Drug therapy of rheumatic diseases during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639168" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8849343" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of immunosuppressive drugs during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3064307" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090480" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26750124" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888948" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566229" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Oral corticosteroid use during pregnancy and risk of preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8895146" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774170" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504818" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32961123" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hydroxychloroquine early in pregnancy and risk of birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33434555" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hydroxychloroquine early in pregnancy and risk of birth defects: don't throw out the baby with the bathwater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222350" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20131283" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Birth outcomes in women who have taken leflunomide during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22307734" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pregnancy outcome in women exposed to leflunomide before or during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407881" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/364401" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Aspirin in pregnancy: maternal and fetal effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9759151" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nonsteroidal anti-inflammatory drugs during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16712713" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Anti-inflammatory and immunosuppressive drugs and reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29460920" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-Term Safety of In Utero Exposure to Anti-TNFαDrugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771477" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608287" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827573" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
